07 - 08 July, 2020
| Online Event
Conference Day 1
10:15 am - 10:20 am
PharmaIQ Welcome
10:20 am - 10:30 am
Chairman's Opening Address
10:30 am - 11:15 am
Cell and Gene Therapy Under Covid-19
- Map the impact of Covid 19 across the Cell and Gene Industry and ascertain key areas of impact
- Discuss the emergent challenges and opportunities in light of Covid-19 for CTG development and commercialisation
- Analyse lessons learned in the past 4 months and how the industry can use this situation to better prepare for the future
11:15 am - 12:00 pm
SARS-CoV-2 Peptivators and the CliniMACS Prodigy Cytokine Capture System
Matthew Cobb -
Clinical Account Manager,
Miltenyi Biotech
- Examine use cases demonstrate the versatility of the CliniMACS Prodigy® Platform in processing of MCS's
12:00 pm - 12:45 pm
Building an Agile Operational Platform for Allogeneic Cell Therapies Under Covid-19
Lior Raviv -
Vice President - Operations and Development,
Pluristem Therapeutics
- Hear how Pluristem have adjusted their operational platform from pre-Covid-19 to now and what they have done to increase platform adaptation and flexibility
- Discuss building a flexible operational framework for allogeneic delivery in Israel and beyond
- Examine ways in which Pluristem were able to adjust their logistical framework and supply networks to increase speed of response and decrease time to patient
12:45 pm - 2:00 pm
Lunch Break
2:00 pm - 2:45 pm
An End-to-End Integrated Solutions Approach to Commercial Viral Vector Manufacturing
Paul Cashen -
Senior Bioprocess Specialist,
Pall Biotech
- Examine how manufacturing readiness is critical for speed-to-market ambitions
- See how leveraging a platform approach is key to supporting speed
- Single, integrated solutions vendor offers strategic benefits
Paul Cashen
Senior Bioprocess SpecialistPall Biotech
2:45 pm - 3:45 pm
Panel Discussion: Strategies to Maintain Development and Minimise Timeline Delays Under Covid-19
Louisa Mathias -
Group Lead, Process Development and Manufacturing,
GammaDelta Therapeutics
Matthew Cobb - Clinical Account Manager, Miltenyi Biotech
- Identify opportunities to adapt your manufacturing and process development strategies to accommodate for the current climate
- Debate the challenges present for materials management and sourcing with border closures and social distancing
- Examine company strategies to minimise clinical and commercialization disruptions
- Discuss key lessons learned under Covid-19 and what it may mean for industry development
